Clinical Trial Update: Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib, ifosfamide, and vinorelbine for recurrent or refractory Hodgkin lymphoma in both adult and pediatric patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• bortezomib, ifosfamide, and vinorelbine tartrate

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-04-10